Alterations in the distribution of Lp‐PLA2 between LDL and HDL were detected in patients with various diseases, including atherosclerosis, dyslipidemias,12 DM,277 and PCOS.278 However, the clinical consequences of these alterations were inadequately determined.12 Furthermore, no data are available regarding the effects of selectively inhibiting LDL‐ or HDL‐associated Lp‐PLA2, as almost all published Lp‐PLA2 inhibitors focus on inhibition of total plasma Lp‐PLA2 activity, which primarily concerns LDL‐associated Lp‐PLA2. Here, PLA2G7 is linked to polycystic ovary syndrome.